XML 37 R25.htm IDEA: XBRL DOCUMENT v3.26.1
Earnings Per Share
 6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic and Diluted Net Loss per Share of Common Stock
Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.
The following table reflects the calculation of basic and diluted loss per common share (in thousands, except per share amounts):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Net loss per ImmunityBio common share – basic and diluted
Numerator:
Net loss attributable to ImmunityBio common stockholders$(230,378)$(92,555)$(863,160)$(222,201)
Denominator:
Weighted-average number of common shares outstanding –
   basic and diluted
1,050,070 888,216 1,038,536 870,786 
Net loss per ImmunityBio common share – basic and diluted$(0.22)$(0.10)$(0.83)$(0.26)
Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted net loss per share. The following table details the number of shares of common stock underlying those securities that were excluded from the computation of weighted-average number of common shares outstanding – diluted (shares in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Related-party convertible note88,447 93,053 88,447 93,053 
Outstanding third-party warrants47,862 35,424 47,862 35,424 
Outstanding stock options23,559 25,931 23,559 25,931 
Outstanding RSUs5,931 9,055 5,931 9,055 
Outstanding related-party warrants1,638 1,638 1,638 1,638 
Total167,437 165,101 167,437 165,101 
The potentially dilutive securities shown in the table above exclude an option to purchase up to approximately $5.0 million of the company’s common stock pursuant to the SPOA entered in connection with the RIPA, as the exercise price cannot be determined until the date of exercise. See Note 10 “Revenue Interest Purchase Agreement” for more information.